Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018
![](/report_cover/2671/melanocortin-receptor-4-mc4r-pipeline-review-h2-2016_en.gif)
Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018
SUMMARY
Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.
Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Infectious Disease and Women's Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Female Hypoactive Sexual Desire Disorder, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis and Prader-Willi Syndrome (PWS).
The latest report Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.
Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Infectious Disease and Women's Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Female Hypoactive Sexual Desire Disorder, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis and Prader-Willi Syndrome (PWS).
The latest report Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
- The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
MallInckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
(liraglutide + setmelanotide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4R for Genetic Disorders and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Jul 23, 2018: Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
Jun 18, 2018: Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies
Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)
Jun 14, 2018: Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide
Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel
May 09, 2018: Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel
Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert
Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Mar 19, 2018: Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
MallInckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
(liraglutide + setmelanotide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4R for Genetic Disorders and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Jul 23, 2018: Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
Jun 18, 2018: Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies
Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)
Jun 14, 2018: Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide
Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel
May 09, 2018: Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel
Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert
Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Mar 19, 2018: Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by MallInckrodt Plc, H2 2018
Pipeline by Palatin Technologies Inc, H2 2018
Pipeline by Rhythm Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by MallInckrodt Plc, H2 2018
Pipeline by Palatin Technologies Inc, H2 2018
Pipeline by Rhythm Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
MallInckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
MallInckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc